Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pharmicell Co., Ltd. (005690.KS)
Seoul, KR
Headquartered in Seoul, South Korea, Pharmicell Co., Ltd. is a biopharmaceutical company established in 2002, actively developing and marketing stem cell treatments across South Korea and globally. The firm operates through two primary segments: Biopharmaceutical Business and Biochemical Business. Its flagship approved product, Cellgram_AMI, leverages a patient's own bone marrow-derived mesenchymal stem cells to enhance heart pumping capacity (ejection fraction) in individuals who have suffered acute myocardial infarction and subsequently undergone coronary angioplasty. Beyond this, Pharmicell is actively progressing several pipeline candidates, including Cellgram_LC for liver ailments, Cellgram_ED targeting impotence, Cellgram_DC for cancer treatment, and Hearticellgram_AM for various cardiac conditions. In its Biochemical division, the company produces crucial intermediates for pharmaceutical raw materials, such as nucleosides, mPEGs, and HDP-tosylate, alongside manufacturing specialized industrial materials like low dielectric constant substances and eco-friendly flame retardants. Furthermore, Pharmicell operates "Twelve," a dedicated stem cell bank, and formulates cosmetics utilizing stem cell culture media.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.34% | -7.12% | -24.13% | -7.64% | -12.33% | +4.02% | +23.46% | +67.04% | -11.76% | +127.27% | +5,334.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+75.9% ★ Q1'26: +35.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+536.9% ★ Q1'26: +38.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+34.2% Q1'26: -7.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+29.6% ★ Q1'26: +35.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+41.4% ★ Q1'26: +44.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.40× ★ Q1'26: 0.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
56.23B
est: 81.60M (+68,806.1%)
|
64.85B
est: 65.00B (-0.2%)
|
114.06B
est: 114.00B (+0.1%)
|
162.50B
162.50B – 162.50B
+42.5% YoY
|
230.00B
230.00B – 230.00B
+41.5% YoY
|
| EBITDA |
8.44B
est: 14.43M (+58,389.7%)
|
9.43B
est: 13.19B (-28.5%)
|
36.81B
est: 23.13B (+59.1%)
|
32.97B
32.97B – 32.97B
+42.5% YoY
|
46.67B
46.67B – 46.67B
+41.5% YoY
|
| EBIT |
5.60B
est: 10.92M (+51,168.0%)
|
6.37B
est: 10.66B (-40.3%)
|
33.78B
est: 18.70B (+80.6%)
|
26.66B
26.66B – 26.66B
+42.5% YoY
|
37.73B
37.73B – 37.73B
+41.5% YoY
|
| Net Income |
3.58B
|
6.33B
est: 6.54B (-3.2%)
|
40.33B
est: 40.33B (0.0%)
|
57.41B
57.41B – 57.41B
+42.3% YoY
|
73.28B
73.28B – 73.28B
+27.7% YoY
|
| SGA |
2.97B
est: 4.85M (+61,101.4%)
|
3.20B
est: 2.75B (+16.4%)
|
3.36B
est: 4.82B (-30.3%)
|
6.87B
6.87B – 6.87B
+42.5% YoY
|
9.73B
9.73B – 9.73B
+41.5% YoY
|
| EPS |
60.00
|
105.51
est: 109.00 (-3.2%)
|
671.97
est: 672.00 (0.0%)
|
956.50
956.50 – 956.50
+42.3% YoY
|
1,221.00
1,221.00 – 1,221.00
+27.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 3/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Biotech 244580.KS | 1.60% | 2.29M | 0.45% |
| 2 | Samsung KODEX Momentum PLUS ETF 244620.KS | 0.78% | 82.3K | 0.30% |
| 3 | Kodex Healthcare 266420.KS | 0.44% | 200.3K | 0.09% |
| 4 | Samsung Kodex Fn Growth ETF 325010.KS | 0.05% | 51.2K | 0.30% |
| 5 | Kodex KOSPI 226490.KS | 0.02% | 159.8K | 0.15% |
| 6 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 905.3K | 0.06% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.96M | 0.06% |
| 8 | Kodex Inno-Tech Active 364690.KS | 0.01% | 2.3K | 0.30% |
| 9 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.01% | 41.2K | 0.44% |
| 10 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 15.8K | 0.56% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyun-Soo Kim | Chief Executive Officer & Chairman of the Board of Director | 1B | male |
| Gil Su Jeong | MD, Head of Biomedical Division & Director | — | male |
| HeeCheol Jeong | MD, Internal Accounting Manager & Controller | — | male |
| Seong Nyun Kim | Vice President & Head of Biochemical Division | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 005690.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
